STARTUP PROFILE

Neurosoft Bioelectronics

COUNTRY
Switzerland
FOUNDED
2020
CATEGORY
Brain-Computer Interface
Developing ultra-soft, foldable neural implants and AI-driven decoding to monitor and modulate brain activity for epilepsy, tinnitus, and rehab.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Seed
MODALITY
ECoG
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Epilepsy
TARGET USER
Clinicians
REGULATORY STAGE
Investigational
Neurosoft Bioelectronics is developing ultra-soft implants intended to reduce tissue damage and improve long-term signal quality in epilepsy and related applications. It sits in the same next-generation implant materials trend as Axoft and INBRAIN, though at an earlier stage of translation.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
10
Neurotech Has Arrived
15 September – 29 September 2026

Neurosoft Bioelectronics partnered with Mila, the Montréal AI institute, to accelerate development of a cortical foundation model. Neurosoft will join Mila's research network, pairing its soft, minimally invasive cortical recording platform with the AI expertise needed to train models on scarce neural data.

#
1
Tracking Neurotech Startups
1 May – 26 May 2026

Neurosoft closed a $7.5M oversubscribed seed round led by Skybound Venture Capital, bringing total funding past $20M. The proceeds will advance the company's soft, stretchable cortical electrode platform, claimed to be up to 1,000x more compliant than other flexible interfaces, and fund early development of a cortical foundation model. Participation by Protocol Labs puts Neurosoft in the same investment portfolio as US BCI leaders including Synchron and Science Corp.

Articles featuring
Neurosoft Bioelectronics